Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Takeda Pharmaceutical's TAK-861?
TAK-861 is a small molecule commercialized by Takeda Pharmaceutical, with a leading Phase III program in Narcolepsy. According to Globaldata,...
Data Insights
TAK-861 by Takeda Pharmaceutical for Type 1 Narcolepsy (Narcolepsy with Cataplexy): Likelihood of Approval
TAK-861 is under clinical development by Takeda Pharmaceutical and currently in Phase III for Type 1 Narcolepsy (Narcolepsy with Cataplexy)....